If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Trulicity ® (dulaglutide) injection
0.75 mg/0.5 mL, 1.5 mg/0.5 mL
For questions regarding this product, please see:
Full Prescribing Information
The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.
TRULICITY® (dulaglutide): QTC Interval
At supratherapeutic doses (4 and 7 mg), Trulicity (dulaglutide) does not prolong QTc.
At supratherapeutic doses (4 and 7 mg), Trulicity® (dulaglutide) does not prolong QTc (Trulicity Package Insert, 2017).
Enclosed Prescribing Information
TRULICITY® (dulaglutide) injection, for subcutaneous use, Lilly
The published reference below is available upon request by contacting 1-800-LillyRx.
Reference
Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.
Date of Last Review: May 09, 2017
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 8pm ET
